adenosine diphosphate has been researched along with Neointima in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, R; Lu, Z; Ma, S; Shen, H; Sun, L; Wei, M | 1 |
| Jakubowski, JA; Mizuno, M; Ohno, K; Sugidachi, A; Tomizawa, A | 1 |
2 other study(ies) available for adenosine diphosphate and Neointima
| Article | Year |
|---|---|
The ADP antagonist MRS2179 regulates the phenotype of smooth muscle cells to limit intimal hyperplasia.
Topics: Adenosine Diphosphate; Animals; Cell Movement; Cell Proliferation; Hyperplasia; Interleukin-1beta; Male; Mice; Mitogen-Activated Protein Kinases; Myocytes, Smooth Muscle; Neointima; Phenotype; Proto-Oncogene Proteins c-akt; Purinergic P2Y Receptor Antagonists; Transplants; Tumor Necrosis Factor-alpha; Vena Cava, Inferior | 2015 |
Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in mice.
Topics: Adenosine Diphosphate; Animals; Aorta; Arterial Occlusive Diseases; Arteries; Carotid Arteries; Chemokine CCL2; Chlorides; Ferric Compounds; Hyperplasia; Inflammation; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred C57BL; Neointima; Platelet Aggregation; Prasugrel Hydrochloride; Pyridines; RNA, Messenger; Thrombosis; Time Factors; Transforming Growth Factor beta1 | 2015 |